Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T18:53:13.396Z.
Calculation as of: 2026-10-06T18:53:13.396Z.
Quote observation: 2026-10-06T18:50:03.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 970d877bc7db717cbed859036c212f4e9de57f4ce891843b12d0c27006da4837
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
Seaport Therapeutics, Inc. Common Stock
Market Cap
$933.04M
PS Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Seaport Therapeutics, Inc. Common Stock (SPTX) | $933.04M | N/A | N/A | N/A | N/A |
| CeriBell, Inc. (CBLL)vs › | $932.25M | 9.14 | 7.97 | 9.20 | 9.20 |
| MoonLake Immunotherapeutics (MLTX)vs › | $932.00M | N/A | N/A | N/A | N/A |
| Kura Oncology, Inc. (KURA)vs › | $936.33M | 12.12 | 10.87 | 10.12 | 10.12 |
| HealthStream, Inc. (HSTM)vs › | $912.77M | 2.84 | 2.39 | 2.83 | 2.81 |
| Savara Inc. (SVRA)vs › | $953.94M | N/A | 67181.56 | 48714.67 | 30216.60 |
| Aktis Oncology, Inc. (AKTS)vs › | $965.04M | 95.93 | 127.87 | 127.87 | 127.87 |
| Bioventus Inc. (BVS)vs › | $898.60M | 1.54 | 1.18 | 0.98 | 0.92 |
| Pacira BioSciences, Inc. (PCRX)vs › | $979.09M | 1.31 | 1.39 | 1.65 | 2.62 |
| Arbutus Biopharma Corp (ABUS)vs › | $882.99M | 4.86 | 37.06 | 52.92 | 39.21 |
The four-quarter calculation detail is unavailable for this stored observation.
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
